证券代码：300760 证券简称：迈瑞医疗 公告编号：2024-030 深圳迈瑞生物医疗电子股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）于近日接到公司控股股东 Magnifice（HK）Limited（以下简称"Magnifice（HK）"）的通知，获悉其将所持有的本公 司部分股份办理了解除质押业务，现将具体内容公告如下： 一、 股东股份解除质押的基本情况 | | 是否为控 股股东或 | | 本次解除质 | 占其所 | 占公司总 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 第一大股 | | 押股份数量 | 持股份 | | 起始日 | | 解除日期 | | 质权人 | | | 东及其一 | | （股） | 比例 | 股本比例 | | | | | | | | 致行动人 | | | | | | | | | | | Magnific ...

Key Points Industry/Company - **Industry**: Not specified in the provided content. - **Company**: Not specified in the provided content. Core Views and Arguments - **Device Update Questions**: The discussion seems to revolve around questions regarding equipment updates, although the specific company or industry is not mentioned. [1] Other Important Content - **Interactive Q&A Session**: The meeting includes an interactive Q&A session with investors, facilitated by Yang Fang. [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][10]. Core Views - The company is actively executing a high-consumption and equipment overall solution strategy, with significant potential for development in smart healthcare [5]. - The company achieved a revenue of 34.932 billion yuan in 2023, representing a year-on-year growth of 15.0%, and a net profit of 11.582 billion yuan, with a year-on-year increase of 20.6% [6]. - The company is expected to benefit from the new medical infrastructure and continuous innovation, with projected net profits of 13.907 billion yuan, 16.726 billion yuan, and 19.990 billion yuan for 2024, 2025, and 2026 respectively [5][6]. Financial Performance Summary - In 2023, the company reported a revenue of 349.3 billion yuan, with a gross margin of 66.2% [5]. - The revenue from life information and support was 152.5 billion yuan, with a gross margin of 66.8% [5]. - The company’s international market growth was nearly 30% in Q1 2024, with a net profit of 31.6 billion yuan, reflecting a year-on-year increase of 22.9% [5][6]. Future Projections - The company expects to achieve a revenue of 41.76 billion yuan in 2024, with a year-on-year growth of 19.5% [6]. - The projected earnings per share (EPS) for 2024, 2025, and 2026 are 11.47 yuan, 13.79 yuan, and 16.49 yuan respectively [6]. - The company aims to continue its transformation into a smart healthcare solution provider, integrating data and AI technologies [5].

Summary of Conference Call Industry Overview - The focus is on the medical device industry, with a positive outlook on future developments, including policy changes and financial progress [1] Core Insights and Arguments - The analysis team expresses optimism regarding the medical device sector's growth potential, indicating a favorable environment for investment [1] Additional Important Content - The call includes an introduction to a deep report on entering the medical field, highlighting the team's commitment to providing comprehensive insights [1]

Financial Data and Key Metrics Changes - The company has maintained a steady growth in R&D investment, with nearly 3.8 billion yuan invested in 2022, accounting for 10.8% of total revenue, representing a year-on-year increase of 28% [10] - The company's revenue for the current year is approximately 21.4 billion yuan, with a market share of about 20% in the domestic market [41] Business Line Data and Key Metrics Changes - The company has three core business areas: Life Information and Support, In Vitro Diagnostics (IVD), and Medical Imaging, with overall gross margins showing a steady upward trend [53] - In the IVD sector, the company has achieved a leading position in various diagnostic fields, including immunodiagnostics and biochemical diagnostics, with significant market share growth [61][63] Market Data and Key Metrics Changes - The domestic medical device market is estimated to be around 780 billion yuan, while the global medical market is approximately 440 billion USD [41] - The company's international business revenue is about 13.5 billion yuan, with a market share in the single digits, indicating substantial growth potential [42] Company Strategy and Development Direction and Industry Competition - The company aims to rank among the top 20 global medical device companies by 2025, with a focus on maintaining a growth rate of over 20% [16][17] - The company emphasizes digitalization and internationalization as key strategic areas, leveraging its three-tiered digital ecosystem to enhance operational efficiency and market reach [40] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery of the domestic market in the second half of the year, driven by ongoing policy support for medical equipment updates and infrastructure development [7][49] - The company anticipates continued growth in the IVD sector, supported by recent acquisitions and product innovations [66] Other Important Information - Recent government policies have outlined significant funding for medical equipment updates, with provinces like Guangdong and Anhui announcing substantial investment plans [2][3][4] - The company has established a strong presence in high-end customer segments, including major hospitals in China and leading healthcare institutions in Europe and the U.S. [14] Q&A Session All Questions and Answers Question: What is the company's outlook on the domestic medical device market? - The company believes that the domestic medical device market will continue to grow, supported by ongoing government initiatives and infrastructure projects [49] Question: How does the company plan to enhance its international presence? - The company is focusing on localizing operations in emerging markets and strengthening partnerships with key distributors to drive growth [52] Question: What are the key areas of innovation for the company moving forward? - The company is prioritizing advancements in digital solutions and AI integration to improve healthcare delivery and operational efficiency [60]

证券代码：300760 证券简称：迈瑞医疗 公告编号：2024-028 深圳迈瑞生物医疗电子股份有限公司 2024年第一次临时股东大会决议公告 一、重要提示 1. 本次股东大会未出现否决议案的情形。 2. 本次股东大会不涉及变更以往股东大会决议。 二、会议召开情况 （一）会议召开时间 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 （1）现场会议：2024年6月12日15:00 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的具体时间为：2024年6月12 日9:15-9:25、9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统进行网络投票的具 体时间为：2024年6月12日9:15至15:00期间的任意时间。 （二）现场会议召开地点：深圳市南山区高新技术产业园区科技南十二路迈瑞总部大厦会 议室 （三）会议召集人 深圳迈瑞生物医疗电子股份有限公司董事会 （四）投票方式 本次会议采取现场投票与网络投票相结合的方式召开。 本次股东大会通过深圳证券交易所交易系统和互联网投票系统向社会公众股股东提供网 络形式的投票平台。 （五）会议 ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2024-029 深圳迈瑞生物医疗电子股份有限公司 2．股东股份累计质押情况 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： | | | 持股 | | 本次质 押前质 | 本次质 押后质 | 占其所 | 占公 | 已质押 | 已质押股份情况 | 未质押 | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | | 数量 | 持股 | 押股份 | 押股份 | 持股份 | 司总 | 股份限 | 占已 | | | 占未 | | | | （股） | 比例 | 数量 | 数量 | 比例 | 股本 | 售和冻 | 质押 | 股份限 | | 质押 | | | | | | （股） | （股） | | 比例 | 结、标 | 股份 | 售和冻 结数量 | | 股份 | | | | | | | | | | 记数量 | 比例 | （股） | | 比例 | | | | | | | | | | （股） | | | | | | ...

FANGDA PARTNERS http://www.fangdalaw.com 中国深圳市福田区中心四路 1 号 电子邮件 E-mail: email@fangdalaw.com 嘉里建设广场 T1 座 9 楼 电 话 Tel.: 86-755-8159-3999 邮政编码：518048 传 真 Fax: 86-755-8159-3900 上海市方达（深圳）律师事务所 关于深圳迈瑞生物医疗电子股份有限公司 2024 年第一次临时股东大会的 法律意见书 致：深圳迈瑞生物医疗电子股份有限公司 上海市方达（深圳）律师事务所（以下简称"本所"）是具有中华人民共和国 法律执业资格的律师事务所。根据相关法律顾问协议，本所指派律师出席深圳迈 瑞生物医疗电子股份有限公司（以下简称"迈瑞医疗"或"公司"）2024 年第一次临 时股东大会（以下简称"本次股东大会"），并就本次股东大会的召集和召开程序、 出席和召集会议人员的资格、表决程序和表决结果等有关事宜出具本法律意见书。 本法律意见书依据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东大会规则》及其他相关中华人民共和国境内已公开颁布并生效的法律、 法规、规章 ...

Financial Data and Key Metrics Changes - The company has increased its domestic market share from 15% to 20% and is gradually targeting 30% [12] - The overseas market share is currently at a few percentage points and requires deeper exploration [12] Business Line Data and Key Metrics Changes - The company is focusing on enhancing its existing product lines, particularly in ultrasound and IVD, aiming for industry-leading performance by 2025 and 2026 [11] - The company has allocated 70-80% of its R&D resources to traditional equipment, with 20-30% directed towards new high-value consumables [7] Market Data and Key Metrics Changes - The company is expanding its presence in high-end markets in Europe and North America, with a focus on public hospitals and teaching hospitals [13] - The company is facing challenges in overseas market development due to regulatory and cultural differences, which require time to navigate [13] Company Strategy and Development Direction - The company aims to provide comprehensive solutions that integrate equipment, IT, and AI, particularly in the domestic market [6] - The strategy includes a dual approach of self-research and acquisitions to enhance capabilities in new business areas [9] Management Comments on Operating Environment and Future Outlook - Management acknowledges the competitive landscape in high-value consumables and emphasizes the need for strong organizational and brand capabilities [7] - The company is optimistic about its ability to scale operations in high-value consumables while maintaining its traditional equipment business [7] Other Important Information - The company is leveraging AI and big data for its products, with a focus on privacy and data security [8] - The company has a strong emphasis on localizing production to enhance its overseas market presence despite challenges [12] Q&A Session Summary Question: How does the company plan to address the challenges in overseas markets? - The company is continuously iterating and seeking local employees who align with its culture to enhance its overseas operations [12] Question: What is the company's strategy for high-value consumables? - The company is learning and adapting its sales strategies for high-value consumables, aiming to master this area within three years [19] Question: How does the company ensure its solutions are not overly dependent on a single vendor? - The company's solutions are designed to be open and can integrate with other brands, although this may come with some costs [18]

Summary of Mindray Medical Conference Call Industry and Company Overview - The conference call focuses on Mindray Medical, a company operating in the medical device industry, particularly in minimally invasive surgery, in vitro diagnostics (IVD), cardiovascular, imaging, and orthopedic sectors [1][3][10]. Key Points and Arguments R&D and Product Development - Mindray is positioned as a latecomer in the minimally invasive surgery sector, needing to first establish product offerings before innovating [1]. - Transitioning from general equipment to personalized consumables presents challenges, particularly in high-value consumables where clinical feedback is crucial for product refinement [2]. - The company aims to enhance its product strength to compete directly with foreign enterprises, focusing on brand power improvement [3]. - R&D project selection is based on market demand and business analysis, with a typical development cycle of 4-5 years [4]. - Future R&D investments will focus on integrating devices with IT and AI, enhancing both information technology and smart solutions [4][5]. Competitive Landscape - The domestic market for high-value consumables is competitive, with many innovative companies struggling to expand their market presence [6]. - Mindray's strategy involves maintaining a strong focus on traditional equipment while gradually increasing investment in new business areas [6]. AI and Technology Integration - AI development is progressing with a focus on multi-device interconnectivity and data analysis, leveraging partnerships for large model development [7]. - Mindray's IT ecosystem, including the Sanray platform, aims to enhance clinical data integration and improve diagnostic capabilities [9]. IVD Business and Market Strategy - The company plans to achieve industry-leading status in IVD by 2025-2026, with significant improvements in product performance and automation [10]. - Localized production is essential for expanding overseas market share, which is currently significantly lower than domestic levels [12]. Sales and Market Expansion - Mindray's market share in China has increased from 15% to 20%, with ambitions to reach 30% [12][19]. - The company is exploring high-end markets in Europe and North America, facing challenges related to regulatory compliance and cultural differences [13]. - The sales strategy for high-value consumables is still evolving, with a goal to master this segment within three years [18]. Cost Reduction and Efficiency - Cost reduction strategies focus on both equipment costs and overall solution offerings, emphasizing lifecycle advantages over initial purchase prices [16]. - Mindray's solutions are designed to be open and compatible with other brands, addressing hospitals' concerns about dependency on a single vendor [17]. Organizational Changes - The restructuring of the overseas marketing organization aims to enhance efficiency and adapt to local market conditions [15]. Additional Important Insights - Mindray's commitment to maintaining a high execution rate in R&D budgets (98%-100%) reflects its strategic focus on innovation and product development [4]. - The company recognizes the importance of building a robust ecosystem that can integrate various products and services, enhancing its competitive edge [9].